Fort Washington Investment Advisors 13F: Exits TECH Stake

Fort Washington Investment Advisors sold its entire position in Bio-Techne Corporation (NasdaqGS: TECH) in a filing on October 15, 2026. The firm cut 470,675 shares, which represented a 100% decrease from its previous holdings. This sale left Fort Washington with zero shares in Bio-Techne, a move reflecting changes in its investment strategy.

Other Institutional Activity in Bio-Techne

Several other institutional investors have adjusted their holdings in Bio-Techne recently. Blackrock Inc. increased its stake by 1,761,199 shares, bringing its total to 14,025,816 shares worth about $1.02 billion. FMR, LLC also added 4,894,819 shares, totaling 12,794,784 shares valued at around $928.5 million. Goldman Sachs Group Inc. raised its holdings by 5,399,772 shares, now owning 7,343,324 shares worth about $532.9 million. Meanwhile, Vanguard Capital Management LLC made a slight addition of 38,684 shares, ending with 10,218,558 shares valued at approximately $741.6 million. HBK Investments L P increased its position by 3,412,500 shares, holding a total of 6,825,000 shares worth about $495.3 million.

Bio-Techne Corporation Stock Down 0.1%

Bio-Techne shares recently traded around $72.47, which is about equal to its 50-day moving average of $72.37. The stock is currently above its 200-day moving average by 15.6% but remains below its 52-week high of $72.69 by about 0.3%. This suggests that the stock is trading closely to its recent highs, indicating some stability in its price movement.

Recent Earnings

For the trailing twelve months, Bio-Techne reported revenue of approximately $1.22 billion, showing a year-over-year growth of 1.3%. The company has an earnings per share (EPS) of $1.16 and a net margin of 15.0%. The next earnings report is scheduled for November 9, 2026.

Insider Buying and Selling at Bio-Techne Corporation

Recent insider transactions include Director Amy E. Herr, who sold 6,636 shares at an average price of $48.28 for a total of $320,386 on May 8, 2026, and another sale of 1,976 shares at an average price of $59.10 for $116,791 on February 17, 2026. Both transactions were completed before the recent filing.

Analysts Set New Price Targets

On June 29, 2026, Citigroup downgraded Bio-Techne to a Neutral rating with a price target of $73. This was followed by TD Cowen, which downgraded the stock to Hold with the same target on June 30, 2026. RBC Capital also downgraded Bio-Techne to Sector Perform with a target of $73 on July 9, 2026. Currently, the consensus rating among analysts is to Hold, with a mean price target of $70.5 based on 10 analyst opinions.

About Bio-Techne

Bio-Techne Corporation develops and sells life science reagents, instruments, and services for research, diagnostics, and bioprocessing. The company operates in the biotechnology sector, serving various markets globally from its headquarters in Minneapolis, MN. The recent changes in holdings by major investors highlight ongoing interest in Bio-Techne's growth potential.

Bottom Line

Investors should keep an eye on Bio-Techne's next earnings date on November 9, 2026, and the potential impacts of recent insider trades and institutional investments. Fort Washington Investment Advisors' recent filing reflects their updated position as of October 15, 2026, and may not represent their current holdings.